Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89481 | 0.80 | TRPA1 (0.55) | TRPA1BACE1 | |
| SCHEMBL1568752 | 0.78 | TRPA1 (0.49) | TRPA1BACE1LMNADRD2CHRM2 | |
| SCHEMBL6261481 | 0.75 | TRPA1 (0.45) | TRPA1LMNADRD2CHRM2HTR1A | |
| SCHEMBL5577001 | 0.74 | TRPA1 (0.51) | TRPA1BACE1SLC6A2HTR2CSLC6A3 | |
| SCHEMBL6261487 | 0.73 | TRPA1 (0.43) | TRPA1LMNADRD2CHRM2HTR1A | |
| SCHEMBL15569954 | 0.73 | TRPA1 (0.43) | TRPA1LMNATSHRBCHE | |
| Dibenzo[B,F][1,4]Thiazepine SCHEMBL696578 | 0.72 | TRPA1 (1.00) | TRPA1GPR84BACE1DRD2SLC6A2 | |
| SCHEMBL4145291 | 0.72 | POLB (0.44) | TRPA1 | |
| SCHEMBL311435 | 0.72 | TRPA1 (0.55) | TRPA1LMNATSHRHTR2CHTR2B | |
| SCHEMBL1132785 | 0.71 | TRPA1 (0.44) | TRPA1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010001407-A2 | SYNTHESIS OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]- PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE AND ITS FUMARATE SALT | INOGENT LABORATORIES PRIVATE LIMITED (IN) | 2010-01-07 | — | — | WO | claimed |
| WO-2006135544-A1 | SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT | CAMBREX CHARLES CITY, INC. (US) | 2006-12-21 | — | — | WO | claimed |
| EP-2888257-A1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | Janssen Pharmaceutica, N.V. (BE) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031600-A1 | HAPTENS OF QUETIAPINE FOR USE IN IMMUNOASSAYS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-27 | — | — | WO | disclosed |
| EP-2403841-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE FUMARATE | Ranbaxy Laboratories Limited (IN) | 2012-01-11 | — | — | EP | disclosed |
| EP-2245021-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | Fermion Oy (FI) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010100623-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE FUMARATE | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010033270-A1 | DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-2144892-A2 | IMPROVED PROCESS FOR PREPARING QUETIAPINE FUMARATE | Teva Pharmaceutical Industries Ltd. (IL) | 2010-01-20 | — | — | EP | disclosed |
| WO-2010001407-A2 | SYNTHESIS OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]- PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE AND ITS FUMARATE SALT | INOGENT LABORATORIES PRIVATE LIMITED (IN) | 2010-01-07 | — | — | WO | disclosed |
| EP-2124957-A1 | METHODS OF TREATING MOOD DISORDERS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009095529-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008121415-A2 | IMPROVED PROCESS FOR PREPARING QUETIAPINE FUMARATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-09 | — | — | WO | disclosed |
| US-20080241949-A1 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-10-02 | — | — | US | disclosed |
| WO-2008116144-A1 | METHODS OF TREATING MOOD DISORDERS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1951258-A2 | LIQUID FORMULATIONS | AstraZeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062339-A2 | LIQUID FORMULATIONS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135544-A1 | SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT | CAMBREX CHARLES CITY, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135544-A1 | SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT | CAMBREX CHARLES CITY, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-0282236-A1 | Process for the preparation of a thiazepine compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241949-A1 | Process for preparing quetiapine fumarate | CYP3A5, CYP3A4, FH | TRPA1 3892/4885GPR84 3168/4885BACE1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.